Abstract
Coronary artery disease (CAD) remains the world’s leading cause of mortality and the disease burden is continually expanding as the population ages. Recently, the MR-INFORM randomised trial has demonstrated that the management of patients with stable CAD can be guided by stress perfusion cardiovascular magnetic resonance (CMR) imaging and it is non-inferior to the using the invasive reference standard of fractional flow reserve. The benefits of using stress perfusion CMR include that it is non-invasive and significantly reduces the number of unnecessary coronary revascularisations. As compared to other ischaemia tests, it boasts a high spatial resolution and does not expose the patient to ionising radiation. However, the main limitation of stress perfusion CMR is that the diagnostic accuracy is highly dependent on the level of training of the operator, resulting in the test only being performed routinely in experienced tertiary centres.The clinical translation of stress perfusion CMR would be greatly aided by a fully automated, user-independent, quantitative evaluation of myocardial blood flow. This thesis presents major steps towards this goal: robust motion correction, automated image processing, reliable quantitative modelling, and thorough validation. The motion correction scheme makes use of data decomposition techniques, such as robust principal component analysis, to mitigate the difficulties in image registration caused by the dynamic contrast enhancement. The motion corrected image series are input to a processing pipeline which leverages the recent advances in image processing facilitated by deep learning. The pipeline utilises convolutional neural networks to perform a series of computer vision tasks including myocardial segmentation and right ventricular insertion point detection. The tracer-kinetic model parameters are subsequently estimated using a Bayesian inference framework. This incorporates the prior information that neighbouring voxels are likely to have similar kinetic parameters and thus improves the reliability of the estimated parameters. The full process is validated in a well characterised patient population against coronary angiography and invasive measurements. It is shown to be accurate at detecting reductions in myocardial blood flow while further discriminating between patients with no significant CAD and those with obstructed coronary arteries or microvascular dysfunction.
Date of Award | 1 Jan 2021 |
---|---|
Original language | English |
Awarding Institution |
|
Supervisor | Amedeo Chiribiri (Supervisor) & Jack Lee (Supervisor) |